<DOC>
	<DOCNO>NCT01774981</DOCNO>
	<brief_summary>The purpose two-part study investigate safety , tolerability efficacy LY3016859 multiple intravenous ( IV ) dose 's participant diabetic nephropathy ( DN ) . Part A dose escalation safety tolerability Part B evaluate Proteinuria .</brief_summary>
	<brief_title>Study LY3016859 Participants With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Stable diabetic kidney disease ( DKD ) take Standard Care medication ( SOC ) , define : Estimated glomerular filtration rate ( eGFR ) less ( &lt; ) 90 milliliter per minute per 1.73 square meter ( ml/min/1.73m² ) determine utilize Modification Diet Renal Disease ( MDRD ) equation Taking angiotensin convertible enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) stable dose great equal ( ≥ ) 2 month prior randomization agree continue take throughout duration study Type 1 Type 2 diabetes stable treatment regimen adequately control opinion investigator First morning proteincreatine ratio ( PCR ) screen ≥400 milligram per gram ( mg/g ) ( Part B ) Clinical chemistry lab within acceptable range participant population , per investigator judgment Men woman nonchildbearing potential determined medical history physical examination Nonvasectomized male participant must agree use medically accept method contraception sexual partner study 90 day follow final dosing . Medically accept effective form contraception may include condom contraceptive foam partner use diaphragms contraceptive jelly cervical cap contraceptive jelly Female participant must postmenopausal surgically sterile participate study . This define female age 45 75 year , inclusive , either 12 month without menstrual period [ follicle stimulate hormone ( FSH ) test require ] 612 month without menstrual period follicle stimulate hormone ( FSH ) great ( &gt; ) 40 international unit per liter ( IU/L ) Must weigh ≥50 kilogram ( kg ) time screen dose Acceptable sit blood pressure ( BP ) per follow American Heart Association ( AHA ) guideline : Normal : systolic blood pressure ( SBP ) &lt; 120 millimeter mercury ( mmHg ) diastolic blood pressure ( DBP ) &lt; 80 mmHg Prehypertension : SBP 120139 DBP 8089 High Blood Pressure ( Hypertension ) Stage 1 : SBP 140159 mmHg DBP 9099 Have give write informed consent prior studyspecific procedure Are reliable willing make available duration study willing follow site specific study procedure Have venous access sufficient allow blood sample Have laboratory value safety parameter , opinion investigator , acceptable fo participation study Have diagnosis chronic kidney disease ( CKD ) DKD , ( hypertensive nephrosclerosis superimpose DKD acceptable ) Have SBP &gt; 160 mmHg DBP &gt; 100 mmHg Individuals Stage 1 BP elevation ( SBP 140159 mmHg DBP 9099 mmHg ) occasion study , may acceptable , long nonproteinlowering antihypertensive adjust achieve target BP goal ( &lt; 140/90 mmHg ) Current use ( within 2 week enrollment ) , project need renin inhibitor aldosterone antagonist , combination Angiotensinconverting enzyme inhibitors/angiotensin II receptor blocker ( ACEi/ARB ) Individuals dialysis transplantation anticipate within 6 month screen Have history acute kidney injury within 3 month screen Are currently enrol , discontinue within last 60 day , clinical trial involve investigational drug receive regulatory approval indication and/or receive treatment biologic agent ( monoclonal antibody ) within 3 month 5 halflives administer drug ( whichever longer ) prior dose Have previously complete withdrawn study study investigate LY3016859 Have diagnosis Class III IV congestive heart failure ( defined New York Heart Association ) Have abnormality 12lead Electrocardiogram ( ECG ) , opinion investigator increase risk associate participate study . In addition , individual follow finding exclude : Confirmed correct QT ( QTcF ) interval &gt; 450 millisecond ( msec ) men &gt; 470 msec woman Irregular rhythms sinus arrhythmia occasional , rare supraventricular ectopic beat History unexplained syncope Family history unexplained sudden death sudden death due long QT syndrome Twave configuration sufficient quality assess QT interval , determine investigator Have evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody ; history cirrhosis hepatitis C positive hepatitis C antibody screen visit ; know hepatitis B surface antigenpositive positive hepatitis B surface antigen screen visit Are unwilling discontinue use Chinese herb least 2 week prior randomization duration study participation Are unwilling unable comply use data collection device directly record data participant Have donate blood 500 milliliter ( mL ) within last 60 day prior screen Have average weekly alcohol intake exceed 21 unit per week unwilling stop alcohol intake within 48 hour entry study duration study ( 1 unit = 12 ounce ( oz ) 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Individuals , opinion investigator , show evidence regular use drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>